Pemetrexed DisodiumThird Party Manufacturing in India

Pemetrexed Disodium works by disrupting folate-dependent metabolic pathways vital for cell replication. It simultaneously inhibits three key enzymes: thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. This multi-targeted inhibition restricts the synthesis of purine and pyrimidine nucleotides, stopping DNA and RNA production in neoplastic cells. Unlike single-target agents like methotrexate, its multi-enzyme blocking mechanism reduces the development of cellular drug resistance. It is highly effective and well-tolerated when paired with vitamin supplementation.

Therapeutic Uses

• Non-Small Cell Lung Cancer: Indicated for non-squamous NSCLC as initial combination therapy and maintenance treatment.
• Malignant Pleural Mesothelioma: Administered in combination with cisplatin for unresectable cases.

Why Manufacturers Choose Pemetrexed Disodium

With expanding treatment indicators for non-squamous lung cancers, Pemetrexed Disodium third party manufacturing in India offers an essential business option for oncology portfolios. Celesta works closely with advanced manufacturing hubs to secure reliable access to high-purity lyophilized vials. Our specialized partners operate within environments where our production facilities are WHO-GMP certified, providing consistent control over trace moisture levels and degradation pathways. This attention to detail guarantees long-term stability and quick dissolution properties for clinical use.